AASLD – The Liver Meeting 2020

infohep news

• Experimental treatments for NASH/NAFLD

  Semaglutide alone or in combination regimens shows promise for NASH

  Liz Highleyman / 18 December 2020

  Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ...

• Experimental treatments for NASH/NAFLD

  Lanifibranor improves NASH in 24-week trial

  Keith Alcorn / 18 December 2020

  Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ...

• Experimental treatments for NASH/NAFLD

  Efruxifermin improves liver fat and fibrosis in people with NASH

  Keith Alcorn / 15 December 2020

  Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ...

• Epidemiology

  Few countries will meet 2020 target for reducing viral hepatitis deaths

  Keith Alcorn / 24 November 2020

  Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ...

• Antiviral therapy

  Some hepatitis B patients can safely stop antivirals

  Liz Highleyman / 24 November 2020

  Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ...

• Finance, funding & health economics

  Can investment in hepatitis C treatment be cost saving?

  Keith Alcorn / 24 November 2020

  Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ...

• Mother to child

  Tenofovir alafenamide prevents mother-to-child hepatitis B virus transmission

  Liz Highleyman / 20 November 2020

  Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to their infants, according to a pair of studies presented ...

• Monitoring response to treatment

  Minimal monitoring of hepatitis C treatment is safe and effective

  Keith Alcorn / 17 November 2020

  Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ...

• New and experimental treatments for hepatitis B

  NASVAC therapeutic vaccine may lead to functional cure of hepatitis B

  Liz Highleyman / 17 November 2020

  NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ...

• Coronavirus

  Fatty liver greatly increases vulnerability to COVID-19 in obese people

  Keith Alcorn / 16 November 2020

  Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ...